Esperion Therapeutics
ESPR
#6486
Rank
A$1.11 B
Marketcap
A$4.31
Share price
55.50%
Change (1 day)
155.13%
Change (1 year)

Earnings for Esperion Therapeutics (ESPR)

Earnings in 2025 (TTM): -A$43.8 Million

According to Esperion Therapeutics's latest financial reports the company's current earnings are A$0.30 Billion. In 2024 the company made an earning of A$10.41 Million, an increase over its 2023 earnings that were of -A$0.21 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Esperion Therapeutics from 2000 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) -A$43.8 Million-520.59%
2024 A$10.41 M-104.99%
2023 -A$0.21 Billion-15.03%
2022 -A$0.25 Billion-20.61%
2021 -A$0.31 Billion84.28%
2020 -A$0.17 Billion35.75%
2019 -A$0.13 Billion-55.71%
2018 -A$0.28 Billion19.57%
2017 -A$0.24 Billion125.39%
2016 -A$0.11 Billion51.43%
2015 -A$68.35 Million36.45%
2014 -A$50.09 Million43.55%
2013 -A$34.9 Million145.26%
2012 -A$14.23 Million
2002 -A$40.57 Million-7.81%
2001 -A$44 Million15.03%
2000 -A$38.25 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Pfizer
PFE
A$14.13 B-37,241.50%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
A$7.25 B-19,161.62%๐Ÿ‡บ๐Ÿ‡ธ USA
Ultragenyx Pharmaceutical
RARE
-A$0.71 Billion 1,754.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Lexicon Pharmaceuticals
LXRX
-A$95.14 Million 149.91%๐Ÿ‡บ๐Ÿ‡ธ USA
Amicus Therapeutics
FOLD
A$0.26 M-100.70%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
A$0.66 B-1,858.24%๐Ÿ‡บ๐Ÿ‡ธ USA